Literature DB >> 19303930

Cerebrospinal fluid beta-glucocerebrosidase activity is reduced in Dementia with Lewy Bodies.

L Parnetti1, C Balducci, L Pierguidi, C De Carlo, M Peducci, C D'Amore, C Padiglioni, S Mastrocola, E Persichetti, S Paciotti, G Bellomo, N Tambasco, A Rossi, T Beccari, P Calabresi.   

Abstract

The autophagy-lysosomal degradation pathway plays a role in the onset and progression of neurodegenerative diseases. Clinical and genetic studies indicate that mutations of beta-glucocerebrosidase represent genetic risk factors for synucleinopathies, including Parkinson's Disease (PD) and Dementia with Lewy Bodies (DLB). We recently found a decreased activity of lysosomal hydrolases, namely beta-glucocerebrosidase, in cerebrospinal fluid of PD patients. We have thus measured the activity of these enzymes - alpha-mannosidase (EC 3.2.1.24), beta-mannosidase (EC 3.2.1.25), beta-glucocerebrosidase (EC 3.2.1.45), beta-galactosidase (EC 3.2.1.23) and beta-hexosaminidase (EC 3.2.1.52) - in cerebrospinal fluid of patients suffering from DLB, Alzheimer's Disease (AD), Fronto-Temporal Dementia (FTD) and controls. Alpha-mannosidase activity showed a marked decrease across all the pathological groups as compared to controls. Conversely, beta-glucocerebrosidase activity was selectively reduced in DLB, further suggesting that this enzyme might specifically be impaired in synucleinopathies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19303930     DOI: 10.1016/j.nbd.2009.03.002

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  26 in total

1.  Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies.

Authors:  S Pablo Sardi; Jennifer Clarke; Catherine Viel; Monyrath Chan; Thomas J Tamsett; Christopher M Treleaven; Jie Bu; Lindsay Sweet; Marco A Passini; James C Dodge; W Haung Yu; Richard L Sidman; Seng H Cheng; Lamya S Shihabuddin
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-07       Impact factor: 11.205

Review 2.  Cerebrospinal fluid biomarkers in Parkinson disease.

Authors:  Lucilla Parnetti; Anna Castrioto; Davide Chiasserini; Emanuele Persichetti; Nicola Tambasco; Omar El-Agnaf; Paolo Calabresi
Journal:  Nat Rev Neurol       Date:  2013-02-19       Impact factor: 42.937

3.  Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.

Authors:  Roy N Alcalay; Oren A Levy; Cheryl C Waters; Stanley Fahn; Blair Ford; Sheng-Han Kuo; Pietro Mazzoni; Michael W Pauciulo; William C Nichols; Ziv Gan-Or; Guy A Rouleau; Wendy K Chung; Pavlina Wolf; Petra Oliva; Joan Keutzer; Karen Marder; Xiaokui Zhang
Journal:  Brain       Date:  2015-06-27       Impact factor: 13.501

Review 4.  Genetic convergence of Parkinson's disease and lysosomal storage disorders.

Authors:  Hao Deng; Xiaofei Xiu; Joseph Jankovic
Journal:  Mol Neurobiol       Date:  2014-08-07       Impact factor: 5.590

5.  cNEUPRO: Novel Biomarkers for Neurodegenerative Diseases.

Authors:  Philipp Spitzer; Hans Wolfgang Klafki; Kaj Blennow; Luc Buée; Hermann Esselmann; Sanna-Kaisa Herruka; Connie Jimenez; Peter Klivenyi; Piotr Lewczuk; Juan Manuel Maler; Katrin Markus; Helmut E Meyer; Chris Morris; Thorsten Müller; Markus Otto; Lucilla Parnetti; Hilkka Soininen; Susanna Schraen; Charlotte Teunissen; Laszlo Vecsei; Henrik Zetterberg; Jens Wiltfang
Journal:  Int J Alzheimers Dis       Date:  2010-09-19

6.  Atp13a2-deficient mice exhibit neuronal ceroid lipofuscinosis, limited α-synuclein accumulation and age-dependent sensorimotor deficits.

Authors:  Patrick J Schultheis; Sheila M Fleming; Amy K Clippinger; Jada Lewis; Taiji Tsunemi; Benoit Giasson; Dennis W Dickson; Joseph R Mazzulli; Mark E Bardgett; Kristi L Haik; Osunde Ekhator; Anil Kumar Chava; John Howard; Matt Gannon; Elizabeth Hoffman; Yinhuai Chen; Vikram Prasad; Stephen C Linn; Rafael J Tamargo; Wendy Westbroek; Ellen Sidransky; Dimitri Krainc; Gary E Shull
Journal:  Hum Mol Genet       Date:  2013-02-07       Impact factor: 6.150

7.  Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease.

Authors:  Karen E Murphy; Amanda M Gysbers; Sarah K Abbott; Nahid Tayebi; Woojin S Kim; Ellen Sidransky; Antony Cooper; Brett Garner; Glenda M Halliday
Journal:  Brain       Date:  2014-01-28       Impact factor: 13.501

Review 8.  Glucocerebrosidase is shaking up the synucleinopathies.

Authors:  Marina Siebert; Ellen Sidransky; Wendy Westbroek
Journal:  Brain       Date:  2014-02-14       Impact factor: 13.501

Review 9.  Cathepsin D-Managing the Delicate Balance.

Authors:  Olja Mijanovic; Anastasiia I Petushkova; Ana Brankovic; Boris Turk; Anna B Solovieva; Angelina I Nikitkina; Sergey Bolevich; Peter S Timashev; Alessandro Parodi; Andrey A Zamyatnin
Journal:  Pharmaceutics       Date:  2021-06-05       Impact factor: 6.321

10.  Bridging molecular genetics and biomarkers in lewy body and related disorders.

Authors:  Gilbert J Ho; Willie Liang; Masaaki Waragai; Kazunari Sekiyama; Eliezer Masliah; Makoto Hashimoto
Journal:  Int J Alzheimers Dis       Date:  2011-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.